期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 24, 期 5, 页码 571-578出版社
KLUWER ACADEMIC/PLENUM PUBL
DOI: 10.1023/B:JOCI.0000040928.67495.52
关键词
antibody; HER-2/neu; vaccine; epitope-spreading; breast; ovarian
类别
资金
- NCI NIH HHS [U54 CA080818, R01 CA75163, K08 CA61834] Funding Source: Medline
- NCRR NIH HHS [M01-RR-00037] Funding Source: Medline
HER-2/neu is a tumor antigen in patients with breast and ovarian cancer. Multiple varieties of vaccine strategies are being developed to immunize patients against HER-2/neu. Studies in animal models have demonstrated both T cell and antibody immunity are needed to mediate an antitumor response. Thirty-five patients, immunized with HER-2/neu peptide based vaccines, were evaluated for the generation of HER-2/neu-specific antibody immunity. Sixty percent of patients developed HER-2/neu IgG specific antibody responses to at least one peptide included in their vaccine. Twenty-nine percent of patients developed IgG immunity to the native HER-2/neu protein after peptide immunization. Humoral intramolecular epitope-spreading within the HER-2/neu protein occurred in 49% of immunized patients. Intermolecular epitope-spreading to p53 was evident in 20% of vaccinated patients. Of those patients who developed new immunity to p53, 71% had demonstrated antibody epitope-spreading within HER-2/neu.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据